BNP/NT-proBNP Cutoffs Stratified for PH (Calculator)
Enter biomarker result
Classify a BNP or NT-proBNP value using one of the pulmonary arterial hypertension risk frameworks.
RISK TOOL
About BNP/NT-proBNP thresholds
Natriuretic peptide concentrations provide information about myocardial wall stress and prognosis in pulmonary arterial hypertension (PAH). Thresholds are interpreted as one part of a multiparametric assessment, rather than as a standalone diagnostic test or complete patient risk classification.
ESC/ERS 2022 — three strata
| Category | BNP | NT-proBNP |
|---|---|---|
| Low | <50 ng/L | <300 ng/L |
| Intermediate | 50–800 ng/L | 300–1100 ng/L |
| High | >800 ng/L | >1100 ng/L |
COMPERA 2.0 — four strata
| Category | BNP | NT-proBNP |
|---|---|---|
| Low | <50 ng/L | <300 ng/L |
| Intermediate-low | 50–199 ng/L | 300–649 ng/L |
| Intermediate-high | 200–800 ng/L | 650–1100 ng/L |
| High | >800 ng/L | >1100 ng/L |
At exact boundary values, the calculator assigns 50 BNP to intermediate, 200 BNP to intermediate-high, 800 BNP to intermediate-high, and values above 800 to high; for NT-proBNP it assigns 300 to intermediate, 650 to intermediate-high, 1100 to intermediate/intermediate-high, and values above 1100 to high. For continuous laboratory values between integer cutoffs, category assignment follows the numerical thresholds.
References
View guideline (DOI)
Important limitations
- These thresholds are intended for risk assessment in PAH, not as a stand-alone screening or diagnostic test for all forms of pulmonary hypertension.
- Natriuretic peptide levels may be affected by other cardiac disease, age, and renal function.
- The COMPERA four-strata tool ordinarily integrates WHO functional class and 6-minute walk distance with the biomarker; this calculator classifies the biomarker component only.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.